Submitted by Ricardo Itapema de Castro Monteiro (ricardo.itapema@gmail.com) on 2018-09-20T22:41:48Z No. of bitstreams: 1 LOF_RM_Final 3.pdf: 277836 bytes, checksum: 5ea1c7ce5f9c454964e2958165915bca (MD5) / Approved for entry into archive by Simone de Andrade Lopes Pires (simone.lopes@fgv.br) on 2018-09-21T17:33:29Z (GMT) No. of bitstreams: 1 LOF_RM_Final 3.pdf: 277836 bytes, checksum: 5ea1c7ce5f9c454964e2958165915bca (MD5) / Approved for entry into archive by Isabele Garcia (isabele.garcia@fgv.br) on 2018-09-24T13:44:41Z (GMT) No. of bitstreams: 1 LOF_RM_Final 3.pdf: 277836 bytes, checksum: 5ea1c7ce5f9c454964e2958165915bca (MD5) / Made available in DSpace on 2018-09-24T13:44:41Z (GMT). No. of bitstreams: 1 LOF_RM_Final 3.pdf: 277836 bytes, checksum: 5ea1c7ce5f9c454964e2958165915bca (MD5) Previous issue date: 2018-08-20 / The accelerated growth of pharmaceutical market in Brazil, in the past ten years, attracted and intensified investments from multinational pharmaceutical companies. National companies also invested heavily. The industry matured and competition intensified. However, a company that operates in a foreign, new environment, driven by unfamiliar competitive forces generally encounters additional costs to operate. This phenomenal is called ‘liability of foreignness’ (LOF). Still, the foreign branch of a company may also have unique advantages due to their being foreign, the so called ‘asset of foreignness’ (AOF). Do these theoretical expectations hold in the Brazilian pharmaceutical industry? The paper employs panel data methodology with fixed effects on four regression models for a sample of 22 companies (11 Brazilian subsidiaries of multinationals and 11 national companies) from this industry. Moreover, the models utilized were proved by other researchers, in different markets segments and countries. The findings support the hypothesis formulated by these scholars and suggest the existence of “Liability of Foreignness”. / O crescimento acelerado do mercado farmacêutico brasileiro nos últimos dez anos atraiu e intensificou os investimentos de empresas farmacêuticas multinacionais. As empresas nacionais também investiram pesadamente. A indústria amadureceu e a concorrência se intensificou. No entanto, uma empresa que opera num ambiente estrangeiro, que é impulsionado por forças competitivas desconhecidas, geralmente se depara com custos adicionais para operar. Este fenômeno é chamado de "Liability of Foreigness" (LOF). Ainda assim, a filial estrangeira de uma empresa também pode ter vantagens exclusivas devido ao fato de serem estrangeiras, o chamado "Asset of Foreingnness" (AOF). Essas expectativas são evidentes na indústria farmacêutica brasileira? O presente trabalho emprega a metodologia de dados em painel com efeitos fixos em quatro modelos de regressão para uma amostra de 22 empresas (11 subsidiárias brasileiras de multinacionais e 11 empresas nacionais) desta indústria. Os modelos utilizados foram comprovados anteriormente por outros pesquisadores, em diferentes segmentos de mercado e países. As descobertas deste trabalho suportam parte das hipóteses formuladas por esses estudiosos e sugerem a existência do “Liability of Foreignnes”.